These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6099724)

  • 1. Cardiovascular pharmacology of ketanserin.
    Van Nueten JM; Vanhoutte PM
    Bibl Cardiol; 1984; (38):222-33. PubMed ID: 6099724
    [No Abstract]   [Full Text] [Related]  

  • 2. 5-hydroxytryptamine and precapillary vessels.
    Van Nueten JM
    Fed Proc; 1983 Feb; 42(2):223-7. PubMed ID: 6295823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive properties of ketanserin (R 41 468).
    Vanhoutte PM; Van Nueten JM; Symoens J; Janssen PA
    Fed Proc; 1983 Feb; 42(2):182-5. PubMed ID: 6295821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can peripheral serotonergic blockade explain the hypotensive effect of ketanserin?
    Vanhoutte PM
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S105-9. PubMed ID: 2412025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketanserin (S2-receptor blocking agent), platelet activity and chronic alcoholism.
    Santini P; Ceccanti M; De Lorenzo A; Pisculli M; Di Giovanni MG; Cavaleri G; Attilia ML; Berbellini A
    Int J Clin Pharmacol Res; 1986; 6(1):73-6. PubMed ID: 2937746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypotensive and antiaggregative effects of eugenosedin-B with serotonin and alpha/beta-adrenoceptor antagonistic activities in rats and human platelets.
    Shen KP; Chu LW; Hsieh SL; An LM; Chen IJ; Wu BN
    J Cardiovasc Pharmacol; 2008 Feb; 51(2):154-61. PubMed ID: 18287883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition by ketanserin of serotonin induced cerebral arteriolar constriction.
    Thompson JA; Wei EP; Kontos HA
    Stroke; 1984; 15(6):1021-4. PubMed ID: 6506113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ketanserin on the hyperreactivity of platelets to 5-hydroxytryptamine in patients with cardiovascular diseases.
    De Cree J; Leempoels J; Demoen B; Roels V; Verhaegen H
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S26-8. PubMed ID: 2412051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Serotonin and cardiovascular diseases].
    Reneman RS; Wenting GJ
    Ned Tijdschr Geneeskd; 1995 Oct; 139(41):2080-4. PubMed ID: 7477565
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of ketanserin on post-anaesthetic vasoconstriction and shivering.
    Nalda MA; Gomar C; Luis M
    Eur J Anaesthesiol; 1985 Sep; 2(3):265-77. PubMed ID: 2933253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there alpha-adrenergic blockade and/or serotonergic blockade during chronic ketanserin treatment?
    Ball SG; Robertson JI
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S120-2. PubMed ID: 2412031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketanserin prevents platelet aggregation and endotoxin-induced pulmonary vasoconstriction.
    Meuleman TR; Hill DC; Port JD; Stanley TH; Pace NL; Mohammad SF
    Crit Care Med; 1983 Aug; 11(8):606-11. PubMed ID: 6872549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular activity of ketanserin (R 41 468), a selective 5-HT2 receptor antagonist.
    Van Nueten JM; Xhonneux R; Vanhoutte PM; Janssen PA
    Arch Int Pharmacodyn Ther; 1981 Apr; 250(2):328-9. PubMed ID: 7271395
    [No Abstract]   [Full Text] [Related]  

  • 14. Prolongation of rat tail bleeding time by ketanserin: mechanisms of action.
    Buczko W; Gambino MC; De Gaetano G
    Eur J Pharmacol; 1984 Aug; 103(3-4):261-8. PubMed ID: 6237923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ketanserin and mepyramine on platelet aggregation and on the uptake of 5-hydroxytryptamine into platelets.
    Bevan J; Heptinstall S
    Thromb Res; 1983 Jun; 30(5):415-23. PubMed ID: 6612677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for an alpha-1 receptor-mediated central sympathoinhibitory action of ketanserin.
    McCall RB; Schuette MR
    J Pharmacol Exp Ther; 1984 Mar; 228(3):704-10. PubMed ID: 6323678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet hypersensitivity to serotonin after prolonged ketanserin intake?
    Arnout J; Van Russelt M; Deckmyn H; Vermylen J; Fiocchi R; Lijnen P; Amery A
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S20-2. PubMed ID: 2412049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the antihypertensive properties of ketanserin (R 41 468) in rats.
    Kalkman HO; Timmermans PB; Van Zwieten PA
    J Pharmacol Exp Ther; 1982 Jul; 222(1):227-31. PubMed ID: 6283070
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of ketanserin on peripheral blood flow, haemorheology, and platelet function in patients with Raynaud's phenomenon.
    Longstaff J; Gush R; Williams EH; Jayson MI
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S99-101. PubMed ID: 2412071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive action and serotonin-induced platelet aggregation during long-term ketanserin treatment in hypertensive patients.
    Amery A; Fagard R; Fiocchi R; Lijnen P; Staessen J; Vermylen J
    J Cardiovasc Pharmacol; 1984; 6(1):182-5. PubMed ID: 6199602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.